dr. michelle berry, professor of tropical diseases and medicine in stanford university. >> these vaccines which have been around for a while, it has not been fast tracked because ebola virus is a disease of people living overseas, not america. it's not going to be a very profitable vaccine. even in the travel medicine arena, not many people are going to be taking ebola vaccine. it's not going to be very profitable. >> you know, that's really the problem right there. there are only 3,000 people who have been affected by ebola, and they live in some of the poorest countries in the world, it's not a good target market for the pharmaceutical industry. >> and what about this sir rum being administered. is that something that we could see go into wider distribution. >> reporter: the problem is because this has been poorly studied there is really no sense at all whether this sir rum has anything to do with dr. brantley's recovery. it's been tested on primates, it's never been tested on humans. we have no way of knowing. the thing about it, there is a lot of interesting tough you could learn abou